203 related articles for article (PubMed ID: 33419778)
1. Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.
Hu N; Wang F; Sun T; Xu Z; Zhang J; Bernard D; Xu S; Wang S; Kaminski M; Devata S; Phillips T; Malek SN
Clin Cancer Res; 2021 Apr; 27(8):2301-2313. PubMed ID: 33419778
[TBL] [Abstract][Full Text] [Related]
2. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE; Burger JA
Front Immunol; 2021; 12():689472. PubMed ID: 34177947
[TBL] [Abstract][Full Text] [Related]
3. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
[TBL] [Abstract][Full Text] [Related]
5. Dual phosphorylation of Btk by Akt/protein kinase b provides docking for 14-3-3ζ, regulates shuttling, and attenuates both tonic and induced signaling in B cells.
Mohammad DK; Nore BF; Hussain A; Gustafsson MO; Mohamed AJ; Smith CI
Mol Cell Biol; 2013 Aug; 33(16):3214-26. PubMed ID: 23754751
[TBL] [Abstract][Full Text] [Related]
6. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
7. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
8. MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
Wu X; Nowakowski KE; Abeykoon JP; Manske M; Stenson MJ; Timm MM; Hanson CA; Van Dyke DL; Dasari S; Witzig TE
Eur J Haematol; 2021 Oct; 107(4):458-465. PubMed ID: 34214199
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.
Paul J; Soujon M; Wengner AM; Zitzmann-Kolbe S; Sturz A; Haike K; Keng Magdalene KH; Tan SH; Lange M; Tan SY; Mumberg D; Lim ST; Ziegelbauer K; Liu N
Cancer Cell; 2017 Jan; 31(1):64-78. PubMed ID: 28073005
[TBL] [Abstract][Full Text] [Related]
10. A Moving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma.
Afaghani J; Taylor J
Clin Cancer Res; 2021 Apr; 27(8):2123-2125. PubMed ID: 33579791
[TBL] [Abstract][Full Text] [Related]
11. CD19 controls Toll-like receptor 9 responses in human B cells.
Morbach H; Schickel JN; Cunningham-Rundles C; Conley ME; Reisli I; Franco JL; Meffre E
J Allergy Clin Immunol; 2016 Mar; 137(3):889-98.e6. PubMed ID: 26478008
[TBL] [Abstract][Full Text] [Related]
12. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
[TBL] [Abstract][Full Text] [Related]
13. Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells.
Linley A; Krysov S; Ponzoni M; Johnson PW; Packham G; Stevenson FK
Blood; 2015 Oct; 126(16):1902-10. PubMed ID: 26194765
[TBL] [Abstract][Full Text] [Related]
14. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
[TBL] [Abstract][Full Text] [Related]
15. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
Moyo TK; Wilson CS; Moore DJ; Eischen CM
Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
[TBL] [Abstract][Full Text] [Related]
16. Bruton's tyrosine kinase is essential for hydrogen peroxide-induced calcium signaling.
Qin S; Chock PB
Biochemistry; 2001 Jul; 40(27):8085-91. PubMed ID: 11434777
[TBL] [Abstract][Full Text] [Related]
17. Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling.
Watanabe D; Hashimoto S; Ishiai M; Matsushita M; Baba Y; Kishimoto T; Kurosaki T; Tsukada S
J Biol Chem; 2001 Oct; 276(42):38595-601. PubMed ID: 11507089
[TBL] [Abstract][Full Text] [Related]
18. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
19. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt.
Craxton A; Jiang A; Kurosaki T; Clark EA
J Biol Chem; 1999 Oct; 274(43):30644-50. PubMed ID: 10521450
[TBL] [Abstract][Full Text] [Related]
20. Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α.
Pontoriero M; Fiume G; Vecchio E; de Laurentiis A; Albano F; Iaccino E; Mimmi S; Pisano A; Agosti V; Giovannone E; Altobelli A; Caiazza C; Mallardo M; Scala G; Quinto I
J Mol Med (Berl); 2019 May; 97(5):675-690. PubMed ID: 30887112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
